Bli medlem
Bli medlem

Du är här


Medivir: Continued strong market uptake for OLYSIO® during the second quarter 2014

Stockholm, Sweden - Medivir AB (OMX: MVIR) announces that the global
second quarter net sales of Olysio (simeprevir) amounted to 831 MUSD,
of which 725 MUSD were sales in the USA. Olysio continued a very
positive sales development and gained market shares during the

Medivir's royalties based on sales for the second quarter amounted to
500,7 MSEK (54,4 MEUR).

OLYSIO® global net sales Sales in MUSD
Market Q2 2014 Q1 2014
US 725 291
RoW 106 63
Total global net sales MUSD 831 354

"The second quarter's royalty from Johnson & Johnson is obviously of
high importance for our company. However, the biggest gain is that so
many patients now can access new and effective treatments for
hepatitis C, like Olysio. This really makes a difference to patients
and is a powerful motivator for all of us in Medivir", says Maris
Hartmanis, Medivir's CEO.

Medivir will publish its second quarter report on August 21, 2014 at
8.30 CET followed by a conference call for investors, analysts and
the media at 14.00 CET. More information about the conference call /
audiocast will be available at

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

Medivir is required under the Securities Markets Act to make the
information in this press release public. The information was
submitted for publication at 13.55 CET on 15 July 2014.

About Olysio®
Olysio is an NS3/4A protease inhibitor jointly developed by Janssen
R&D Ireland and Medivir AB and indicated for the treatment chronic
hepatitis C infection in combination with pegylated interferon and
ribavirin in HCV genotype 1 and 4 infected patients with compensated
liver disease, including cirrhosis.

Janssen is responsible for the global clinical development of Olysio
and has exclusive, worldwide marketing rights, except in the Nordic
countries. Medivir AB retains marketing rights for Olysio in these
countries under the marketing authorization held by Janssen-Cilag
International NV. Olysio was approved for the treatment of chronic
hepatitis C infection as part of an antiviral treatment regimen in
combination with pegylated interferon and ribavirin in genotype 1
infected adults with compensated liver disease, including cirrhosis
in September 2013 in Japan, in November 2013 in Canada and the U.S.
and in March 2014 in Russia. Following the EMA approval, it is
anticipated that Olysio will be available across a number of European
Union countries in conjunction with reimbursement, in the second half
of 2014. Olysio (simeprevir) is marketed under the trade name
Sovriad® in Japan and Russia, Galexos™ in Canada and Olysio® in the
U.S. and European Union.

About Medivir
Medivir is an emerging research-based pharmaceutical company focused
on infectious diseases. Medivir has world class expertise in
polymerase and protease drug targets and drug development which has
resulted in a strong infectious disease R&D portfolio. The Company's
key pipeline asset is Olysio, a novel protease inhibitor for the
treatment of hepatitis C that is being developed in collaboration
with Janssen R&D Ireland. The company is also working with research
and development in other areas, such as bone disorders and
neuropathic pain. Medivir has also a broad product portfolio with
prescription pharmaceuticals in the Nordics.


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.